Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
narcolepsy
Biotech
Alkermes races to phase 3 after posting another narcolepsy win
Alkermes reported another phase 2 win for its narcolepsy candidate, succeeding where Takeda failed to maintain its hopes of being first to market.
Nick Paul Taylor
Nov 12, 2025 9:30am
Takeda drops AZ-partnered neurological program after ph. 2 fail
Oct 30, 2025 9:25am
Takeda, Alkermes lift lid on narcolepsy rivals as race heats up
Sep 8, 2025 6:47am
Chasing Takeda, Alkermes reports phase 2 narcolepsy win
Jul 21, 2025 8:40am
Takeda narcolepsy blockbuster hopeful secures double ph. 3 wins
Jul 14, 2025 5:51am
Alkermes impresses in full-throttle narcolepsy race with Takeda
Jun 4, 2024 9:01am